Bruker Corp. (NASDAQ:BRKR) – Equities research analysts at Leerink Swann issued their Q1 2017 earnings per share (EPS) estimates for shares of Bruker Corp. in a research note issued to investors on Wednesday. Leerink Swann analyst P. Souda anticipates that the brokerage will post earnings per share of $0.22 for the quarter. Leerink Swann has a “Market Perform” rating and a $21.00 price objective on the stock. Leerink Swann also issued estimates for Bruker Corp.’s Q2 2017 earnings at $0.19 EPS, Q3 2017 earnings at $0.28 EPS, Q4 2017 earnings at $0.40 EPS, FY2018 earnings at $1.20 EPS and FY2019 earnings at $1.25 EPS.

Bruker Corp. (NASDAQ:BRKR) last announced its earnings results on Wednesday, November 2nd. The company reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.12. The business earned $393.90 million during the quarter, compared to the consensus estimate of $394.14 million. Bruker Corp. had a net margin of 9.02% and a return on equity of 26.05%. The firm’s revenue was down .6% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 earnings per share.

Earnings History and Estimates for Bruker Corp. (NASDAQ:BRKR)

A number of other equities analysts have also recently weighed in on BRKR. BTIG Research reiterated a “neutral” rating on shares of Bruker Corp. in a report on Friday, July 22nd. Cleveland Research cut Bruker Corp. from a “buy” rating to a “neutral” rating in a report on Friday, July 22nd. Zacks Investment Research cut Bruker Corp. from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 27th. Mizuho lowered their price target on Bruker Corp. from $28.00 to $23.00 and set a “neutral” rating for the company in a report on Wednesday, August 3rd. Finally, Wells Fargo & Co. cut Bruker Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 3rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $25.73.

Bruker Corp. (NASDAQ:BRKR) opened at 22.87 on Friday. The firm has a 50-day moving average of $21.68 and a 200-day moving average of $23.61. Bruker Corp. has a one year low of $19.59 and a one year high of $29.85. The company has a market capitalization of $3.68 billion, a P/E ratio of 25.84 and a beta of 1.04.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Veritable L.P. increased its position in shares of Bruker Corp. by 0.3% in the second quarter. Veritable L.P. now owns 13,091 shares of the company’s stock valued at $298,000 after buying an additional 33 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Bruker Corp. by 0.3% in the second quarter. PNC Financial Services Group Inc. now owns 17,853 shares of the company’s stock valued at $406,000 after buying an additional 47 shares during the period. Neuberger Berman Group LLC increased its position in shares of Bruker Corp. by 0.3% in the second quarter. Neuberger Berman Group LLC now owns 31,800 shares of the company’s stock valued at $723,000 after buying an additional 81 shares during the period. Seven Eight Capital LLC increased its position in shares of Bruker Corp. by 2.6% in the second quarter. Seven Eight Capital LLC now owns 11,700 shares of the company’s stock valued at $266,000 after buying an additional 300 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Bruker Corp. by 4.1% in the second quarter. Legal & General Group Plc now owns 8,460 shares of the company’s stock valued at $192,000 after buying an additional 335 shares during the period. Hedge funds and other institutional investors own 69.70% of the company’s stock.

Bruker Corp. Company Profile

Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

5 Day Chart for NASDAQ:BRKR

Receive News & Stock Ratings for Bruker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corp. and related stocks with our FREE daily email newsletter.